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Abstract: The neuronal nitric oxide synthase gene (NOS1) is located at 12q24, a susceptibility region for schizophrenia, 
and produces nitric oxide (NO). NO has been reported to play important roles as a gaseous neurotransmitter in brain. NO 
is a second messenger for the N-methyl-D aspartate (NMDA) receptor and is related to the dopaminergic system. Because 
the symptomatology of methamphetamine (METH) use disorder patients with psychosis is similar to that of patients with 
schizophrenia, NOS1 is a good candidate gene for METH-induced psychosis. Therefore, we conducted a case-control  
association study between NOS1 and METH-induced psychosis with Japanese subjects (183 with METH-induced   
psychosis patients and 519 controls). We selected seven SNPs (rs41279104, rs3782221, rs3782219, rs561712, rs3782206, 
rs6490121, rs2682826) in NOS1 from previous reports. Written informed consent was obtained from each subject. This 
study was approved by the Ethics Committee at Fujita Health University School of Medicine and each participating insti-
tute of the Japanese Genetics Initiative for Drug Abuse (JGIDA). No significant association was found between NOS1 and 
METH-induced psychosis in the allele/genotype-wise or haplotype-wise analyses. In conclusion, we suggest that NOS1 
might not contribute to the risk of METH-induced psychosis in the Japanese population. 
Keywords: Methamphetamine-induced psychosis, neuronal nitric oxide synthase 1 gene (NOS1), case-control association 
study. 
1. INTRODUCTION 
  Methamphetamine (METH) is a drug that is used widely 
in the world and causes psychiatric disorder. METH causes 
abnormalities of the dopamine neural transmission in the 
mesolimbic system, and is thought to cause psychotic symp-
toms such as hallucinations and delusions [1, 2]. 
  Nitric oxide (NO) is involved a variety of mechanisms, 
regulating the release of neurotransmitters such as dopamine 
and serotonin, activating N-methyl-D-aspartate (NMDA) 
receptor, and participating in oxidative stress [3-5]. There-
fore, NO functions may be considered to induce psychotic 
disorders. The nitric oxide synthase 1 gene (NOS1) is a   
complex gene located at 12q24, consisting of 12 alternative 
untranslated first exons, termed exon 1a_1l, and 28 exons in 
a genomic region spanning 149.404Kb. NOS1 is considered  
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to be a likely candidate gene for schizophrenia owing to its 
chromosomal location, 12q24, which has been reported to be 
a susceptibility locus from several linkage studies, and to 
play a role in producing NO in the human brain [6-8].  
  Several genetic association studies showed that single 
nucleotide polymorphisms (SNPs) in NOS1 were associated 
with schizophrenia. Reif et al. identified functional SNP 
(rs41279104) in the promoter region and found an associa-
tion with schizophrenia [9]. Two other genetic association 
studies showed a significant association between rs2682826 
in exon 29 and haplotype (rs3782221-rs3782219-rs561712-
rs3782206) and schizophrenia. Recently, a whole genome 
association study reported an association between rs6490121 
in intron 2 of NOS1 and schizophrenia [12]. Therefore, 
NOS1 is recognized to be candidate gene for schizophrenia 
[10, 11]. 
  Because the symptoms of METH-induced psychosis are 
similar to those of paranoid type schizophrenia, it may be 
that the METH-induced psychosis and schizophrenia have 
common susceptibility genes. Therefore, it would be of in-156    Current Neuropharmacology, 2011, Vol. 9, No. 1  Okumura et al. 
terest to examine the association between NOS1 and METH-
induced psychosis. We conducted a genetic association 
analysis in the Japanese population.  
2. MATERIALS AND METHODS 
2.1. Subjects 
  The subjects in the association analysis were 183 patients 
(all patients were diagnosed as having METH-induced psy-
chosis; 151 males and 32 females: mean age ± SD 36.7±11.6 
years) and 519 healthy controls (268 males and 251 females: 
mean age ± SD 37.5 ±14.4 years). All subjects were unre-
lated to each other, ethnically Japanese, and lived in Japan. 
Among the subjects with METH use disorder, all subjects 
had a comorbid diagnosis of METH-induced psychosis. One 
hundred forty-nine subjects with METH use disorder abused 
or had dependence on drugs other than METH. Cannabinoids 
were the most frequency abused drugs (31.4%), followed by 
cocaine (9.09%), LSD (9.09%), opioids (7.69%), and hyp-
notics (7.69%). Subjects with METH use disorder were ex-
cluded if they had a clinical diagnosis of psychotic disorder, 
mood disorder, anxiety disorder, or eating disorder. The pa-
tients were diagnosed according to DSM-IV or ICD-10 crite-
ria with consensus of at least two experienced psychiatrists 
on the basis of unstructured interviews and a review of 
medical records. All healthy controls were also psychiatri-
cally screened through unstructured interviews, and those 
with past individual or family history of drug dependence or 
an axis 1 disorder such as psychotic or mood disorder were 
excluded. After describing the study, written informed con-
sent was obtained from each subject. This study was ap-
proved by the Ethics Committee at Fujita Health University 
and each participating institute of the Japanese Genetics   
Initiative for Drug Abuse (JGIDA). 
2.2. SNP Selection and Genotyping 
  We selected seven SNPs (rs2682826, rs3782221, rs3782219, 
rs561712, rs3782206, rs41279104, rs6490121) in NOS1 from 
previous association studies for schizophrenia [9-11]. We used 
TaqMan assays (Applied Biosystems) for all SNPs.  
2.3. Statistical Analysis 
  Genotype deviation from the Hardy-Weinberg equilib-
rium (HWE) was evaluated with the chi-square test 
(SAS/Genetics, release 8.2, SAS Japan INC, Tokyo, Japan). 
Marker-trait association was also evaluated with the chi-
square test in allele- and genotype-wise analyses. Haplotype 
frequencies were estimated in a two- to four-marker sliding 
window fashion and log likelihood ratio tests were per-
formed for global P-values with COCAPHASE program 
version 3.0.6 [13]. In these haplotype-wise analyses, rare 
haplotypes (less than 0.05) of either cases or controls were 
excluded from the association analysis. Power calculation 
was performed using a statistical program prepared with   
the Genetic Power Calculator (http://pngu.mgh.harvard. 
edu-/~purecell//gpc/). The level of significance for all statistical 
tests was 0.05. 
3. RESULTS 
  Genotype frequencies of subjects and controls did not 
deviate significantly from HWE. No significant association 
was found between NOS1 and METH-induced psychosis in 
the allele/genotype-wise analysis, or in the haplotype analysis 
(Table 1, 2). Our METH samples were unmatched gender 
Table 1.  Association Study Between  NOS1 and METH-Induced Psychosis 
Genotype Distribution
c  P- value 
SNP ID  Phenotype
a MAF
b N 
M/M M/m m/m HWE
d Genotype Allele 
rs41279104  METH-induced psychosis  0.175   183  123  56  4  0.413  0.684  0.983 
  CON  0.175    519  354  148 17 0.751    
rs3782221  METH-induced psychosis  0.421   183  61  90  32  0.903  0.912  0.891 
 CON  0.425    519  175  247  97  0.55    
rs3782219  METH-induced psychosis  0.423   183  61  89  33  0.956  0.611  0.332 
  CON  0.453    519 154 260 105 0.803    
rs561712  METH-induced psychosis  0.161   183  128  51  4  0.679  0.716  0.435 
  CON  0.179    519  346  160 13 0.274    
rs3782206  METH-induced psychosis  0.265   183  100  69  14  0.663  0.745  0.44 
  CON  0.245    519  300  184 35 0.351    
rs6490121  METH-induced psychosis  0.407   183  62  93  28  0.475  0.523  0.532 
  CON  0.426    519  175  246 98 0.484    
rs2682826  METH-induced psychosis  0.380   183  67  93  23  0.286  0.175  0.0754 
   CON  0.329   519  230  237  52  0.424       
a METH:methamphetamine  CON: control 
b MAF: minor allele frequency 
c M: major allele, m: minor allele 
d Hardy-Weinberg equilibrium. Genetic Association Analysis of NOS1 and Methamphetamine-Induced  Current Neuropharmacology, 2011, Vol. 9, No. 1    157 
samples for METH-induced psychosis. Therefore, we per-
formed an explorative analysis of gender effects, but no as-
sociation was detected between any of the SNPs and either 
sex (Table 3). 
  In a power analysis, we obtained more than 80% power 
for the detection of association when we set the genotype 
relative risk at 1.37-1.6, under a multiplicative model of   
inheritance. 
4. DISCUSSION 
  We did not find an association between the seven SNPs 
in  NOS1 and METH-induced psychosis in the al-
lele/genotype-wise or haplotype-wise analysis in these sub-
jects. In several genetic studies of METH, gender effects 
were found in METH use disorder [14, 15]. Because we rec-
ognize that our gender samples were unmatched, our nega-
tive result may have mainly reflected the effect of male 
METH-induced psychosis. We therefore conducted an ex-
plorative analysis of gender effects, but found none. Since 
NO has an important role in regulating the release of neuro-
transmitters such as dopamine and serotonin, NOS1 is recog-
nized to be a good candidate gene for disorder with psycho-
sis. However, a previous study did not report an association 
between NOS1 and schizophrenia [16]. Other genes involved 
in the activity of NOS1 may be related to the pathophysiol-
ogy of psychotic disorders such as schizophrenia and 
METH-induced psychosis. 
  Nitric oxide synthase 1 adaptor protein (NOS1AP) en-
codes an adapter protein that binds to NOS1 and links to a 
specific target. Recent studies reported evidence of a signifi-
cant association between NOS1AP and schizophrenia [17, 
18]. Considering these positive results, it will be necessary to 
replicate the studies using other larger population samples 
and other phenotypes, such METH-induced psychosis. 
  A few points of caution must be mentioned with regard 
to our present negative findings. (1) It is important to evalu-
ate associations between METH use disorder with and with-
out psychosis. However, since we had only a small number 
of subjects without psychosis, we did not evaluate this asso-
ciation to avoid type I error due to small sample size. to the 
small number of subjects was a result of limitations of sam-
ple collection, since we recruited cases of METH use disor-
der in psychiatric hospitals. (2) We could not adopt an LD-
based strategy and mutation scan, because NOS1 has a mas-
sive gene structure. Therefore, in future studies it will be 
necessary to evaluate associations between other common 
variants or rare variants with functional effects and NOS1 in 
METH use disorder.  
  In conclusion, our results suggest that NOS1 does not 
play a major role in METH use disorder with psychosis in 
the Japanese population. However, the number of METH 
samples used in this study was small, and even though it is 
difficult to find samples of METH use disorder, it will be 
necessary to validate or replicate our association in other, 
larger population samples.  
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Table 2.  Haplotype-Wise Analysis Between NOS1 and METH-Induced Psychosis 
   Global P-value
SNP ID  2 Window  3 Window  4 Window
rs41279104     
 0.631    
rs3782221   0.576  
 0.336    0.755
rs3782219   0.541  
 0.385    0.799
a
rs561712   0.683  
 0.756    0.673
rs3782206   0.810    
 0.428    0.871
rs6490121   0.868  
 0.769   
rs2682826     
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